

## Special Issue

# Flavivirus Immunotherapy

### Message from the Guest Editor

As the of the Vaccines Special Issue “Flavivirus Immunotherapy”, I would like to invite you to contribute with an original report, original observation, commentary, or review to it. As you are perfectly aware, flaviviruses (Flaviviridae family) are arthropod-borne viruses, whose genomes are composed of a single RNA molecule of positive polarity. Vaccines are only available for a few flaviviruses and there is no specific therapy on the market for any of them. Thereby, to achieve a more comprehensive understanding of the current trends in flavivirus immunoprophylaxis, this Special Issue of Vaccines is dedicated to recent scientific and technical progress made in this field. Based on your extensive experience and your recent publications, it would be our honor to publish your work to support the global scientific community. We sincerely hope that you accept our invitation. If you can contribute, please let us know at your earliest convenience, and we will provide you with additional details.

---

### Guest Editor

Prof. Dr. Juan Carlos Saiz

Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain

---

### Deadline for manuscript submissions

closed (31 March 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/66379](https://mdpi.com/si/66379)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).